USA flag logo/image

An Official Website of the United States Government

Structure-Stabilized GPCRs for Functional Analysis and Crystallography

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85885
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
MH081380
Solicitation Year:
N/A
Solicitation Topic Code:
NIMH
Solicitation Number:
N/A
Small Business Information
LUCIGEN CORPORATION
2905 PARMENTER ST. Middleton, WI 53562-2547
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: Structure-Stabilized GPCRs for Functional Analysis and Crystallography
Agency: HHS
Contract: 2R44MH081380-02
Award Amount: $1,461,160.00
 

Abstract:

DESCRIPTION (provided by applicant): G-Protein coupled receptors (GPCRs) are a large family of proteins expressed on the surface of eukaryotic cells. They are the major pathway for transducing extracellular signals into a diversity of intracellular respons es. Because of their accessibility and physiological significance, GPCRs are the targets of approximately 30-50% of drugs on the market. GPCRs are of particular significance for mental health, since they include the receptors most neurotransmitters and are the targets of many antipsychotic and antidepressant medications, as well as drugs of abuse. However, further understanding of GPCR function is hampered by a lack of detailed structural information. The current proposal seeks to hasten the path to GPCR st ructure determination and structure/function studies. In Phase I we developed new tools for high-throughput cloning and membrane expression of GPCRs in E. coli. Phase II research will be centered on 10 human GPCRs implicated in brain function and mental he alth. We will seek to express milligram quantities of the proteins, using different transmembrane guides and indicator fusion partners. We will evaluate the proper folding of GPCRs by assaying ligand-binding activity. GPCRs that can be expressed to high le vels in active form will be subject to an iterative process of solubilization, crystallization trials, and structural stabilization efforts, until suitable crystals are obtained. If necessary, we will use genetic schemes to develop modified E. coli strains for improved GPCR expression. We will also develop a system for mammalian cell expression of GPCRs that are inactive or poorly expressed in E. coli. This method will be based on cytoplasmic expression from a linear shuttle vector; importantly, the vector will be useful for bacterial expression as well. Anticipated products include novel bacterial and mammalian expression systems; bacterial and eukaryotic membrane fractions expressing GPCRs for ligand screening; GPCRs with fluorescent tags for assay develop ment; contract expression of GPCRs for structural studies; and structural data from GPCRs for structure-based drug design. PUBLIC HEALTH RELEVANCE: G-Protein Coupled Receptors (GPCRs) are a major pathway through which cells respond to external signa ls, such as light, odors, hormones, or neurotransmitters. However, these proteins are difficult to express, and their detailed structure is not known. In this Phase II proposal, we plan to produce large amounts of brain-derived GPCRs to analyze their cryst al structure. These studies will generate novel protein expression systems as well as structural data that can be used for basic and clinical studies of GPCRs.

Principal Investigator:

Eric J. Steinmetz
6082655704

Business Contact:

Mead David
dmead@lucigen.com
Small Business Information at Submission:

LUCIGEN CORPORATION
LUCIGEN CORPORATION 2120 W GREENVIEW DR, STE 9 MIDDLETON, WI -

EIN/Tax ID: 139192330
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No